Nanologica AB NICA
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait/hold until the company delivers 1–2 quarters of stable underlying operating performance and cash flow from the combined CDMO platform. Watch Q2 (27 Aug) for organic trends, integration costs, and order intake.
The Q2 report showed strong revenue growth but continued negative cash flow and liquidity risk, supporting retention of the HOLD signal until profitability and cash flow stabilize.
Sentiment remains pressured by concerns over cash position and the need for order conversion during H2.
HOLD is the call. Negative is the market mood. High risk means a lot can go wrong.
Latest change
- 1 Sep 2026 — Report released 31 August showed growth from Syntagon acquisition but weaker result and cash, triggering the share drop.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeBull case
Syntagon integration can drive higher capacity utilization and profitability in H2 2026 if the sales organization delivers.
Bear case
Low cash and negative operating cash flow increase the risk of further capital needs before the business reaches break-even.
Why this signal
The Q2 report showed strong revenue growth but continued negative cash flow and liquidity risk, supporting retention of the HOLD signal until profitability and cash flow stabilize.
Recent news
The period after mid-September has been marked by continued price decline to around 0.25 SEK in October without new press releases from the company. Major shareholder Flerie has highlighted Nanologica as a drag on its portfolio and retail investors express growing frustration over missing orders.